"The package collectively targets several aspects of the pharmaceutical landscape, including pharmaceutical benefit manager (PBM) pricing practices, next-generation drug releases, patent portfolio assertions, and use of [FDA] regulatory mechanisms.... [It] is significant that the six bills were moved to the full Senate with bipartisan support."  MORE >>